SynthesisPloS one2015
Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 101 citations in OpenAlex.
- Association of Coffee Intake With Risk of Gastroesophageal Reflux Disease and Complications: A Systematic Review and Meta-Analysis.Clinical and translational gastroenterology · 2026Pooled it
- Pooled it
- Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption.Nature communications · 2021Pooled it
- Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2019Pooled it
- Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes.BMJ (Clinical research ed.) · 2017Pooled it
- Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease : Austrian Society of Gastroenterology and Hepatology (ÖGGH), Austrian Society of Diabetology (ÖDG), Austrian Society of Obesity (ÖAG).Wiener klinische Wochenschrift · 2025Article
- Effect of coffee and coffee extract on liver function test in non-alcoholic fatty liver disease patients, a systematic review and meta-analysis.Gastroenterology and hepatology from bed to bench · 2025Review
- The Role of Dietary Ingredients and Herbs in the Prevention of Non-Communicable Chronic Liver Disease.Nutrients · 2024Review
- Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective.Hepatology international · 2024Review
- Reassessing the Impact of Coffee Consumption on Liver Disease: Insights from a Large-Scale Cohort Study with IPTW Adjustment.Nutrients · 2024Article
- Nanoemulsions ofAntioxidants (Basel, Switzerland) · 2024Article
- Coffee and Microbiota: A Narrative Review.Current issues in molecular biology · 2024Review
- Caffeine mitigates tamoxifen-induced fatty liver in Wistar rats.Acta cirurgica brasileira · 2024Article
- Article
- Treatment Options and Continuity of Care in Metabolic-associated Fatty Liver Disease: A Multidisciplinary Approach.European cardiology · 2024Review
- Beverages - a scoping review for Nordic Nutrition Recommendations 2023.Food & nutrition research · 2024Article
- Compensated liver cirrhosis: Natural course and disease-modifying strategies.World journal of methodology · 2023Review
- Effects of coffee intake on airway hypersensitivity and immunomodulation: anNutrition research and practice · 2023Article
- The Effect of Coffee in the Prevention of Oral Mucositis Associated with Head and Neck Radiotherapy.Florence Nightingale journal of nursing · 2023Article
- Coffee-Derived Exosome-Like Nanoparticles: Are They the Secret Heroes?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPrevious studies have demonstrated that coffee consumption may be inversely correlated with hepatic fibrosis and cirrhosis. However, the reported results have been inconsistent. To summarize previous evidences quantitatively, a meta-analysis was performed.
methodsThe Medline, Web of Science, and Embase databases (from inception to June 2015) were searched to identify relevant trials that evaluated the effects of coffee consumption on hepatic fibrosis or cirrhosis. Odds ratios (ORs) of advanced hepatic fibrosis or cirrhosis for low or moderate, high, and any coffee consumption versus no consumption were pooled. Two cups per day was used as the cut-off level between low or moderate and high consumption.
resultsSixteen studies were included, involving 3034 coffee consumers and 132076 people who do not consume coffee. The pooled results of the meta-analysis indicated that coffee consumers were less likely to develop cirrhosis compared with those who do not consume coffee, with a summary OR of 0.61 (95%CI: 0.45-0.84). For low or moderate coffee consumption versus no consumption, the pooled OR of hepatic cirrhosis was 0.66 (95%CI: 0.47-0.92). High coffee consumption could also significantly reduce the risk for hepatic cirrhosis when compared with no coffee consumption (OR = 0.53, 95%CI: 0.42-0.68). The effect of coffee consumption on hepatic fibrosis was summarized as well. The pooled OR of advanced hepatic fibrosis for coffee consumption versus no consumption was 0.73 (95%CI: 0.58-0.92). The protective effect of coffee on hepatic fibrosis and cirrhosis was also identified in subgroup meta-analyses of patients with alcoholic liver disease and chronic hepatitis C virus (HCV) infection.
conclusionCoffee consumption can significantly reduce the risk for hepatic fibrosis and cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.